This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or registerLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcasts3D Body AtlasLet’s connectLet's connectContact usSign up

Adverse event reporting can be found at the bottom of the page

Home

Menu

Close

EfficacyEfficacy Home PageTrial DesignClinical RemissionEarly Symptomatic ResponseEndoscopic ImprovementBio/JAKi Subgroups DataIsolated ProctitisSafetyAdverse eventsCardiac and ocular adverse eventsGetting StartedResourcesMaterialsVideosPrescribing InformationPrescribing Information 
Early Symptomatic Response

VELSIPITY® helped quickly calm the chaos of UC symptoms

Symptomatic response vs placebo as early as day 21

  • This was a post hoc analysis of daily e-diary data collected on rectal bleeding (RB) and stool frequency (SF) from patients enrolled in the ELEVATE UC 52 and ELEVATE UC 12 trials1 
  • Daily Mayo, RB and SF subscores and partial modified Mayo score (pMMS; RB subscore + SF subscore), as well as change from baseline during the first 28 days of therapy, were calculated from patient e-diary responses1
  • The Mantel–Haenszel weighted test was used to assess the adjusted risk differences in proportions of responders between treatment groups1
ReferencesAdjusted differences with nominal P values of P<0.05 were considered significant.1Adjusted differences were based on estimated common risk difference using Mantel–Haenszel weights and stratified by actual naive to Biologic/JAKi therapy at study entry (Yes/No), actual baseline corticosteroid use (Yes/No), and actual baseline disease activity (an mMS of 4 to 6 or an mMS of 7 to 9).1The Mantel–Haenszel weighted test was used to assess the adjusted risk differences in proportions of responders between treatment groups.1Symptomatic response was defined as patients with a ≥30% change from baseline decrease in a partial modified Mayo score (pMMS).1Bowel urgency

VELSIPITY® helped calm bowel urgency vs placebo

A greater proportion of patients experienced clinically meaningful improvements in bowel urgency with VELSIPITY® vs placebo in ELEVATE UC 522

 ReferencesClinically meaningful improvement in bowel urgency defined as BU NRS ≥3-point decrease from baseline (BU NRS ≤1).2Endoscopic improvement

See how patients achieved endoscopic improvement with VELSIPITY®.

 SEE ENDOSCOPIC DATA Loading▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.References:Dubinsky MC, Vermeire S, Chaparro M, et al. Symptomatic improvement observed within 2 days of etrasimod induction therapy: results from ELEVATE UC 52 and ELEVATE UC 12 studies in patients with ulcerative colitis. United European Gastroenterol J. 2023;11(suppl 8):201-534. Poster presented at: 31st United European Gastroenterology (UEG) Week 2023; Oct 14-17, 2023; Copenhagen, Denmark. Abstract ID: MP359. https://onlinelibrary.wiley.com/doi/epdf/10.1002/ueg2.12460. Accessed December 18, 2023.Dubinsky M, Bleakman AP, Panaccione R, et al. Bowel urgency in ulcerative colitis: current perspectives and future directions. Am J Gastroenterol. 2023;118(11):1940-1953.Legal Category S1A
Further information available on request

PP-V1A-0024 Date of preparation February 2025Efficacy

Adverse events should be reported.

If you wish to make a medical information inquiry or report an adverse event please contact Pfizer on 1800 633 363 
or email Pfizer at [email protected] or visit www.PfizerMedicalInformation.ie

Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.Registered in the Republic of Ireland No. 127002. Directors: M. Adamson (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.

 

Copyright © 2025 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0937. July 2025
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0901. July 2025
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0901. July 2025

Yes No